Abbott Laboratories (ABT) Posts Positive SonicForce Trial Data, Is The Stock A Bargain?
Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash
Abbott Laboratories (ABT) recently announced positive results from its TECTONIC study for the SonicForce Coronary Intravascular Lithotripsy System, meeting safety and effectiveness goals with a 97% procedural success rate. Despite a mixed short-term stock performance, analysts consider ABT undervalued, with fair value estimates ranging from Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context